GSK, Theravance report Ph3 successes for COPD treatment

GlaxoSmithKline and Theravance are giving analysts a thumbs-up on their late-stage studies of Relovair, the next-gen COPD successor to Advair. Investigators say that the drug bested a placebo in the trials. A head-to-head trial pitting Relovair against Advair is underway. "Successful completion of these two studies is an important milestone in the development of Relovair for COPD," said Darrell Baker, head of Glaxo's respiratory medicine development program. "These data will be reviewed together with the larger 12-month exacerbation studies still under way, to develop a complete evaluation of Relovair in treating patients with COPD." Report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.